title: An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
abstract: The impact of erectile dysfunction is distressing to both males and their female partners, but less attention has been paid to identify female partners' preferred treatment and sexual quality of life outcomes. The present analysis explores female partners' treatment preference for erectile dysfunction in Chinese Men. This was a phase 4, randomized, open-label, multicenter, crossover study in Chinese men with erectile dysfunction who were naïve to phosphodiesterase type 5 inhibitor treatments. Eligible patients were randomized to sequential 20-mg tadalafil/100-mg sildenafil or 100-mg sildenafil/20-mg tadalafil for 8 weeks each. Of 418 patients, female partners of 64 patients agreed to enter the study; of 64 patients who entered the study with female partners, 63 were randomized, and 62 completed the study. Baseline demographics and disease characteristics were comparable between treatment groups. Significantly more couples preferred tadalafil compared with sildenafil overall (75.4% vs 24.6%; P < 0.001), and irrespective of erectile dysfunction severity at baseline (P ≤ 0.005). Significant improvements in sexual quality of life scores were reported at endpoint (Visit 8) in male patients and female partners in both tadalafil and sildenafil treatment groups (P < 0.001). Significantly higher mean changes from baseline were observed for male patients in the tadalafil group compared with the sildenafil group for the erectile function (P = 0.013) and overall satisfaction (P = 0.019) International Index for Erectile Function domains and the spontaneity domain (P < 0.001) of the Psychological and Interpersonal Relationship Scale. No major safety concerns were reported during the study. Though both treatments were effective, safe, and tolerable, more couples preferred tadalafil compared with sildenafil.
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Beijing 100730, China.
authors.forename: Hong-Jun
authors.initials: HJ
authors.lastname: Li
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Bai
authors.affiliation: Department of Andrology, Nanjing Drum Tower Hospital, Jiangsu 210008, China.
authors.forename: Yu-Tian
authors.initials: YT
authors.lastname: Dai
authors.affiliation: Department of Medical, Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai 200021, China.
authors.forename: Wen-Ping
authors.initials: WP
authors.lastname: Xu
authors.affiliation: Department of Medical, Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai 200021, China.
authors.forename: Chia-Ning
authors.initials: CN
authors.lastname: Wang
authors.affiliation: Department of Urology, Peking Union Medical College Hospital, Beijing 100730, China.
authors.forename: Han-Zhong
authors.initials: HZ
authors.lastname: Li
mesh_terms: D018592:Cross-Over Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology*; D012725:Sexual Behavior / Q000523:psychology*; D012747:Sexual Partners / Q000523:psychology*; D000068677:Sildenafil Citrate / Q000627:therapeutic use; D000068581:Tadalafil / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil; D000068677:Sildenafil Citrate